Medline Inc. (FRA:L10)
| Market Cap | 28.41B |
| Revenue (ttm) | 26.25B +12.1% |
| Net Income | 614.64M -45.3% |
| EPS | 0.70 +998.4% |
| Shares Out | n/a |
| PE Ratio | 46.23 |
| Forward PE | 15.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Open | 31.40 |
| Previous Close | 31.40 |
| Day's Range | 31.40 - 31.40 |
| 52-Week Range | 27.40 - 42.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Medline
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam g... [Read more]
Financial Performance
In 2025, Medline's revenue was $28.43 billion, an increase of 11.47% compared to the previous year's $25.51 billion. Earnings were $1.16 billion, a decrease of -3.42%.
Financial numbers in USD Financial StatementsNews
Medline price target lowered to $43 from $45 at Barclays
Barclays lowered the firm’s price target on Medline (MDLN) to $43 from $45 and keeps an Overweight rating on the shares as part of a Q3 earnings preview. The firm…
MDLN Investor Reminder: BFA Law Reminds Medline Investors that Lost Money when Stock Dropped 13% of the Ongoing Securities Fraud Investigation
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Kaplan Fox is Investigating Medline Inc. (MDLN) for Investors Who Suffered Losses
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Medline to report third quarter 2026 results on November 4, 2026
NORTHFIELD, Ill., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report third quarter 2026 financial results on Wednesday, November 4, 2026....
MDLN Stock Notice: Medline Stock Plummeted 13% after Product Quality Issues Disclosed - Securities Fraud Investigation Underway
BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- Leading securi...
MDLN Investigation Notification: Medline is Under Investigation for Securities Fraud over Product Quality Issues – Contact BFA Law if You Suffered Losses
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
$MDLN Shareholder Notice: A Securities Fraud Investigation is Ongoing on behalf of Medline Investors with Losses – Contact BFA Law
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Kaplan Fox Reminds Investors of Medline Inc. (MDLN) of an Ongoing Securities Investigation
New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
$MDLN Investigation Notification: Suffer Losses on Your Medline Investment? BFA Law Reminds Investors of the Ongoing Securities Fraud Investigation
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its...
MDLN Investor Investigation: Medline Under Investigation for Securities Fraud on behalf of Investors with Losses – Contact BFA Law
BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Sept.
Medline price target lowered to $43 from $45 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Medline (MDLN) to $43 from $45 and keeps a Buy rating on the shares.
Kaplan Fox Advises Investors of Medline Inc. (MDLN) to Contact the Firm Regarding a Securities Investigation
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
$MDLN Stock Notification: Medline Inc. is Being Investigated for Securities Fraud after Product Quality Issues Disclosed – Investors are Alerted to Contact BFA Law
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Kaplan Fox Notifies Investors of Medline Inc. (MDLN) of a Securities Law Investigation
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Kaplan Fox Encourages Medline Inc. (MDLN) Investors to Contact the Firm Regarding a Securities Investigation
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Kaplan Fox Alerts Investors of Medline Inc. (MDLN) to a Securities Law Investigation
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Medline Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong top-line growth and market share gains were offset by external headwinds and operational investments, leading to a reduced EBITDA outlook. Strategic focus remains on brand conversion, automation, and expansion into new markets, with robust M&A capacity and ongoing technology innovation.
Kaplan Fox Announces an Investigation into Medline Inc. (MDLN) on Behalf of Investors
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
NORTHFIELD, Ill., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are sche...
Kaplan Fox Notifies Medline Inc. (MDLN) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN)...
Kaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Kaplan Fox Encourages Investors of Medline Inc. (MDLN) to Contact the Firm to Learn About Their Legal Rights
New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Kaplan Fox is Investigating Medline Inc. (MDLN) for Potential Violations of the Federal Securities Laws
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Medline price target lowered to $46 from $53 at JPMorgan
JPMorgan lowered the firm’s price target on Medline (MDLN) to $46 from $53 and keeps an Overweight rating on the shares.
Medline price target lowered to $55 from $62 at Tigress Financial
Tigress Financial lowered the firm’s price target on Medline (MDLN) to $55 from $62 and keeps a Buy rating on the shares. The firm views the recent fire-related weakness in…